Interleukin-6 and melanoma

被引:69
|
作者
Hoejberg, Lise [1 ,2 ]
Bastholt, Lars [1 ]
Schmidt, Henrik [3 ]
机构
[1] Odense Univ Hosp, Dept Oncol, DK-5000 Odense C, Denmark
[2] Univ So Denmark, Inst Clin Res, Odense, Denmark
[3] Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark
关键词
biomarker; interleukin-6; melanoma; C-REACTIVE PROTEIN; SERUM INTERLEUKIN-6; CIRCULATING INTERLEUKIN-6; LEVELS CORRELATE; RHEUMATOID-ARTHRITIS; PROGNOSTIC-FACTOR; GROWTH INHIBITOR; CANCER; RECEPTOR; TUMOR;
D O I
10.1097/CMR.0b013e3283543d72
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Interleukin-6 (IL-6) is a pleiotropic immunomodulatory cytokine produced by various types of cells, including melanoma cells. IL-6 plays a major role in the pathogenesis and development of malignancies. It promotes tumour growth by inhibition of apoptosis and induces tumour angiogenesis. IL-6 is deregulated in many types of cancers, and increased serum concentration of IL-6 has been correlated with a worse prognosis in patients with different cancers, including melanoma. Several serum cytokines including IL-6 play an important role in the development and progression of melanoma; however, the specific biological functions of IL-6 in progression of melanoma are unknown. In 1:his review, we present studies on cell cultures and mouse models and summarize published clinical studies on IL-6 and melanoma. Melanoma Res 22:327-333 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:327 / 333
页数:7
相关论文
共 50 条
  • [1] The Role of Interleukin-6 in the Melanoma Metastasis
    Seok, S.
    Na, Y.
    [J]. JOURNAL OF THE AMERICAN ASSOCIATION FOR LABORATORY ANIMAL SCIENCE, 2010, 49 (05): : 732 - 732
  • [2] Is there any relationship between interleukin-6/interleukin-6 receptor modulation and endogenous interleukin-6 release in metastatic malignant melanoma patients treated by biochemotherapy?
    Mouawad, R
    Khayat, D
    Merle, S
    Antoine, EC
    Gil-Delgado, M
    Soubrane, C
    [J]. MELANOMA RESEARCH, 1999, 9 (02) : 181 - 188
  • [3] MELANOMA-DERIVED INTERLEUKIN-6 INHIBITS IN-VIVO MELANOMA GROWTH
    ARMSTRONG, CA
    MURRAY, N
    KENNEDY, M
    KOPPULA, SV
    TARA, D
    ANSEL, JC
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1994, 102 (03) : 278 - 284
  • [4] THE EFFECT OF MELANOMA DERIVED INTERLEUKIN-6 ON MELANOMA GROWTH AND DEVELOPMENT IN A MURINE MODEL
    ARMSTRONG, CA
    KOPPULA, SV
    TARA, DC
    ANSEL, JC
    [J]. CLINICAL RESEARCH, 1991, 39 (02): : A481 - A481
  • [5] REGULATION OF INTERLEUKIN-6 AND INTERLEUKIN-6 RECEPTOR EXPRESSION
    BAUER, J
    GEROK, W
    [J]. BIOLOGICAL CHEMISTRY HOPPE-SEYLER, 1990, 371 (03): : 186 - 186
  • [6] Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma
    Hoejberg, Lise
    Bastholt, Lars
    Johansen, Julia S.
    Christensen, Ib Jarle
    Gehl, Julie
    Schmidt, Henrik
    [J]. MELANOMA RESEARCH, 2012, 22 (04) : 287 - 293
  • [7] The role of interleukin-6 and interleukin-6/interleukin-6 receptor-α complex in the pathogenesis of multiple myeloma
    Barillé, S
    Bataille, R
    Amiot, M
    [J]. EUROPEAN CYTOKINE NETWORK, 2000, 11 (04) : 546 - 551
  • [8] DOWN-REGULATION OF INTERLEUKIN-6 RECEPTOR-ALPHA CHAIN IN INTERLEUKIN-6 TRANSDUCED MELANOMA-CELLS CAUSES SELECTIVE RESISTANCE TO INTERLEUKIN-6 BUT NOT TO ONCOSTATIN-M
    SILVANI, A
    FERRARI, G
    PAONESSA, G
    TONIATTI, C
    PARMIANI, G
    COLOMBO, MP
    [J]. CANCER RESEARCH, 1995, 55 (10) : 2200 - 2205
  • [9] Interleukin-6
    Song, MC
    Kellum, JA
    [J]. CRITICAL CARE MEDICINE, 2005, 33 (12) : S463 - S465
  • [10] INTERLEUKIN-6
    LOTZ, M
    [J]. CANCER INVESTIGATION, 1993, 11 (06) : 732 - 742